Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 3 Trial of JKN2401 Injection in COPD
Sponsor: Joincare Pharmaceutical Group Industry Co., Ltd
Summary
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous JKN2401 Injection in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
Official title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous JKN2401 Injection in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
Key Details
Gender
All
Age Range
40 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
888
Start Date
2026-03
Completion Date
2027-11
Last Updated
2026-01-14
Healthy Volunteers
No
Interventions
JKN2401 Injection
JKN2401 subcutaneous injection, Q4W
Placebo
Placebo subcutaneous injection,Q4W